- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Akums reported strong Q1 FY27 results. Revenue surged 13.9% YoY to ₹1,167 Cr, EBITDA grew 35.4% to ₹175 Cr, and PAT hit ₹101 Cr. CDMO business was the key driver, fueled by volume growth.
All announcements from Akums Drugs and Pharmaceuticals Limited